← Back to Clinical Trials
Recruiting NCT05236465

A 3-day Course for CFS/ME

Trial Parameters

Condition Chronic Fatigue Syndrome
Sponsor Norwegian University of Science and Technology
Study Type INTERVENTIONAL
Phase N/A
Enrollment 100
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2022-03-21
Completion 2027-01-01
Interventions
A 3-day courseWaiting list

Brief Summary

Chronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME) can be a serious and disabling condition with a heavy symptom burden and low function. Work disability is common, and social life dramatically affected. CFS/ME is a challenging health problem as well as a societal problem. In recent years, a doubling of the number of patients with a CFS/ME diagnoses has been reported in Norway. The patient group represents a challenge for the health care system, the municipality, and the Norwegian Labour and Welfare Organization (NAV). According to new figures, the NAV pays 100 million Norwegian Kroner (NOK) each month in permanently incapacitated expenses for people with CFS/ME. Municipalities have expenses in form of care, rehabilitation and other measures. There is a lack of effective treatment for CFS/ME. Evidence-based knowledge is highly needed. If the 3-day course shows promising effects, this could have positive consequences for patients, relatives and health personnel, but also financially for the society and the municipality.

Eligibility Criteria

Inclusion Criteria: * CFS/ME diagnosis based on the Canada Consensus Criteria. * At least 50% out of school/work. * Readiness to change (corresponding to the preparation phase in transtheoretical model) * Has given informed consent. Exclusion Criteria: * Assessed by a General Practitioner (GP): * Underlying physical illness or mental disorder that may explain the symptoms. * Suicide risk/previous suicide attempts. * Pregnancy. * Bedridden and in need of continuous care. * Insufficient Norwegian speaking or writing skills to participate in the 3-day course and fill out questionnaires.

Related Trials